Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF +3.13%77 3-Year EBITDA Growth Rate is 3.10% as of Dec. 2025, which is 87% below its 10-year median of 23.30. GuruFocus rates ERFSF with a GF Score™ of 77/100 and a GF Value™ of $75.36 (Fairly Valued). The stock has 7 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 61.08% on this metric.
During the past 12 months, Eurofins Scientific SE's average EBITDA Per Share Growth Rate was 14.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 14.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Eurofins Scientific SE was 41.60% per year. The lowest was -5.30% per year. And the median was 23.30% per year.
Eurofins Scientific SE (OTCPK:ERFSF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Eurofins Scientific SE 3-Year EBITDA Growth Rate Related Terms
ERFSF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's 3-Year EBITDA Growth Rate falls into.
Eurofins Scientific SE 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.10% mean?
Eurofins Scientific SE (ERFSF) has a 3-Year EBITDA Growth Rate of 3.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Eurofins Scientific SE and its competitors. This is 87% below median its historical median of 23.30. According to the industry distribution chart, Eurofins Scientific SE ranks #102 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 61.1%.
Is Eurofins Scientific SE's 3-Year EBITDA Growth Rate too high?
Eurofins Scientific SE's current 3-Year EBITDA Growth Rate of 3.10% is 87% below median its 10-year median of 23.30. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Eurofins Scientific SE's value of 3.10% is 71.8% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #102 out of 167 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #102 out of 167 companies for 3-Year EBITDA Growth Rate. This places Eurofins Scientific SE in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. Eurofins Scientific SE's value of 3.10% is 71.8% below this benchmark. While the company's 10-year median is 23.30 vs. the industry median of 11.00, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current 3-Year EBITDA Growth Rate of 3.10% is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current 3-Year EBITDA Growth Rate is 3.10%, which is 87% below median its own 10-year median of 23.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.36, compared to a current price of $80.57 — trading 6.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.10%, which is 87% below median its 10-year median of 23.30 and 71.8% below the Medical Diagnostics & Research industry median of 11.00. Eurofins Scientific SE's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current 3-Year EBITDA Growth Rate is 3.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $80.57 is trading 6.9% above its estimated GF Value™ of $75.36.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
3-Year EBITDA Growth Rate: 3.10% (87% below median its 10-year median of 23.30)
GF Value™: $75.36 vs. price of $80.57 (6.9% above fair value)
Industry Position: 71.8% below the Medical Diagnostics & Research median (#102 of 167)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for ERFSF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
